Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Cell. 2020 Oct 15;183(2):301-302. doi: 10.1016/j.cell.2020.09.053.
Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
奥特等人报告了一项 1B 期研究的结果，该研究将个体化新抗原疫苗与程序性死亡受体-1 阻断联合用于晚期癌症患者。该研究为组合疫苗疗法提供了一个框架，这种疗法可以引发强烈的 T 细胞反应、增强肿瘤杀伤作用并提供临床获益。
